Abstract
Assessment of small molecule compounds against filoviruses, such as Ebola virus, has identified numerous compounds that appear to have antiviral activity and should presumably be further investigated in animal efficacy trials. However, despite the many compounds that are purported to have good antiviral activity in in vitro studies, there are few instances where any efficacy has been reported in nonhuman primate models. Many of the high-throughput screening assays use reporter systems that only recapitulate a portion of the virus life cycle, while other assays only assess antiviral activity at relatively early time points. Moreover, many assays do not assess virus progeny production. A more in-depth evaluation of small numbers of test compounds is useful to economize resources and to generate higher quality antiviral hits. Assessing virus progeny production as late as 5 days post-infection allows for the elimination of compounds that have initial antiviral effects that are not sustained or where the virus rapidly develops resistance. While this eliminates many potential lead compounds that may be worthy of further structure-activity relationship (SAR) development, it also quickly excludes compounds that in their current form are unlikely to be effective in animal models. In addition, the inclusion of multiple assays that assess both cell viability and cell cytotoxicity, via different mechanisms, provides a more thorough assessment to exclude compounds that are not direct-acting antivirals.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McMullan LK, Flint M, Dyall J, Albarino C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF (2016) The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus. Antivir Res 125:71–78. doi:10.1016/j.antiviral.2015.10.010
Long J, Wright E, Molesti E, Temperton N, Barclay W (2015) Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000 Res 4:30. doi:10.12688/f1000research.6085.2
Huggins J, Zhang ZX, Bray M (1999) Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 179(Suppl 1):S240–S247. doi:10.1086/514316
Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S (2009) Development of a broad-spectrum antiviral with activity against Ebola virus. Antivir Res 83(3):245–251. doi:10.1016/j.antiviral.2009.06.001
Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, Simmons JA, Grenier JM, Pierce LT, Pajouhesh H, Lehar J, Hensley LE, Glass PJ, White JM, Olinger GG (2015) A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity Sci Transl Med 7 (290):290ra289. doi:10.1126/scitranslmed.aaa5597
Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496):402–405. doi:10.1038/nature13027
Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S (2010) Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 54(5):2152–2159. doi:10.1128/AAC.01315-09
Panchal RG, Reid SP, Tran JP, Bergeron AA, Wells J, Kota KP, Aman J, Bavari S (2012) Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antivir Res 93(1):23–29. doi:10.1016/j.antiviral.2011.10.011
Bray M, Driscoll J, Huggins JW (2000) Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antivir Res 45(2):135–147
Garrison AR, Giomarelli BG, Lear-Rooney CM, Saucedo CJ, Yellayi S, Krumpe LR, Rose M, Paragas J, Bray M, Olinger GG Jr, McMahon JB, Huggins J, O'Keefe BR (2014) The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antivir Res 112:1–7. doi:10.1016/j.antiviral.2014.09.012
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531(7594):381–385. doi:10.1038/nature17180
Ebihara H, Theriault S, Neumann G, Alimonti JB, Geisbert JB, Hensley LE, Groseth A, Jones SM, Geisbert TW, Kawaoka Y, Feldmann H (2007) In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 196(Suppl 2):S313–S322. doi:10.1086/520590
Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hygiene 27(3):493–497
Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H (2011) Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 204(Suppl 3):S1066–S1074. doi:10.1093/infdis/jir348
Chou TC, N. M (2005) CompuSyn for drug combinations and for general dose-effect analysis. ComboSyn Inc., Paramus, NJ
Falzarano D, Safronetz D, Prescott J, Marzi A, Feldmann F, Feldmann H (2015) Lack of protection against ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis 21(6):1065–1067. doi:10.3201/eid2106.150176
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Falzarano, D. (2017). Assessment of Inhibition of Ebola Virus Progeny Production by Antiviral Compounds. In: Hoenen, T., Groseth, A. (eds) Ebolaviruses. Methods in Molecular Biology, vol 1628. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7116-9_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7116-9_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7115-2
Online ISBN: 978-1-4939-7116-9
eBook Packages: Springer Protocols